Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PR!
Endonovo Therapeutics Signs Distribution Agreement with Plagens Medical Consultants for its Pain Relief Electroceutical™ SofPulse®
BY GlobeNewswire
— 1:30 PM ET 05/09/2018
LOS ANGELES, CA, May 09, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. ("Endonovo" or the "Company"), a commercial-stage developer of Electroceutical™ Therapies, today announced a distribution agreement with Plagens Medical Consultants for the distribution of SofPulse™, its non-invasive Electroceutical™ Therapy for post-operative pain relief and reduction of swelling.
SofPulse™ is the Company's FDA-Cleared Electroceutical™ System for the palliative treatment of post-operative pain and edema in superficial soft tissues. SofPulse™ is an easy-to-place, non-invasive device delivering targeted MicroCurrent Therapy (tMCT) to enhance post-surgical recovery. tMCT is an innovative process using proprietary technology to reduce pain and swelling. The therapy is non-invasive and non-pharmacologic, with no known side effects and no potential for overdose or dependency. SofPulse™ has been used effectively and studied extensively in soft tissue post-operative management. The low levels of microcurrent are completely safe and, in fact, are 1000 times lower than those emitted by a mobile phone.
The Company's Electroceutical™ Therapy has been evaluated in 5 randomized, double-blind controlled clinical trials demonstrating:
300% decrease in mean pain scores at 5 hours post-surgery;
2.2-fold reduction in narcotic use post-surgery in active users; and
275% lower mean IL-1 beta (inflammatory biomarker) in the wound exudates of active users following surgery
Endonovo's non-invasive pain relief therapy, SofPulse®, represents a low-cost, drug free solution to the over use of opioids following surgical procedures. Following surgery, many patients will head home with prescriptions for 30 or more opioid painkillers, which is enough to trigger addiction. However, the American Society of Anesthesiologists recommends using prescription painkillers sparingly, if at all, after surgery. Post-surgical prescription practices have played a role in the opioid epidemic and despite the risk of dependence, many surgery patients receive opioid prescriptions for a month's supply or more. Furthermore, about 6 percent of surgery patients are still using opioid painkillers three months or longer after their surgery, according to a study published last year in JAMA Surgery.
Non-invasive electrotherapies, such as Endonovo's SofPulse®, are believed to modulate pain signaling through activation of peripheral endogenous opioids and opioid receptors; making these non-pharmacological devices an extremely safe and economical alternative to prescription painkillers.
Alan Collier, Endonovo Chief Executive Officer, stated, “We are pleased to establish this partnership with Plagens Medical Consultants and I look forward to collaborating with their team to bring SofPulse to a national level. Plagens is a great partner for the SofPulse brand, possessing the scale, infrastructure, reputation, clinical experience and complementary product portfolio to make SofPulse a market leader in post-surgical pain management, recovery and rehabilitation. We are excited Plagens recognized the quality, robustness, innovation and design quality of SofPulse."
"Plagens Medical Consultants, a medical device company established in 1978 and with over 65 years of combined leadership experience, is proud to announce its partnership with Endonovo. Plagens is confident Endonovo's SofPulse will effectively address the opioid problems associated with orthopedic injuries and surgical recovery while providing a non-pharmaceutical option for patients. The feedback we have received on SofPulse from Physicians and other providers has been remarkable. Plagens is anxious to bring this to market in Michigan and the surrounding Great Lakes area." - Jason Walters, Senior Shareholder / Partner, Plagens Medical Consultants.
The distribution agreement may be expanded with additional products and territories in the future. Financial terms of the agreement were not disclosed.
About Plagens Medical Consultants
Since 1978, Plagens has specialized in supplying a diverse range of musculoskeletal devices to hospitals and healthcare providers in Michigan and the surrounding Great Lakes area. In 2013, Plagens expanded its distribution to include products for surgical and non-surgical pain management as well as recovery and rehabilitation. www.plagens.com
About Endonovo Therapeutics ( ENDV
Loading... Loading...
)
Endonovo Therapeutics, Inc. ( ENDV
Loading... Loading...
) is a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ Therapies addresseses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) dDisorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ System device , SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticalss™ addresses chronic kidney disease, liver diseasenon-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's non-invasive, wearable Electroceuticals™ work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. www.endonovo.com
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investor Relations Contact:
Endonovo Therapeutics (
Have you (or anyone) received a straight answer from Andrew/Steve as to why a legitimate company would gag the TA? Just curious what purpose this serves.
Congrats Craig!
I’m betting they’ll use it to dump more dilution...
Endonovo Therapeutics Highlights Feasibility Study Results of Its Electroceutical Therapy in Reducing Proteinuria in Chronic Kidney Disease Patients
GlobeNewswireMay 1, 2018
Company to Conduct Larger Clinical Study to Evaluate Its Electroceutical™ Therapy in Chronic Kidney Disease
LOS ANGELES, CA, May 01, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapies, today announced that it is targeting the treatment of chronic kidney disease (CKD) using its non-invasive Electroceutical™ Therapy and is currently planning a follow-up clinical study to evaluate its Electroceutical™ Therapy for reducing Proteinuria in CKD patients. Additionally, the Company highlighted positive results from an early feasibility study of its Electroceutical™ Therapy in reducing Proteinuria in 4 patients with CKD. The abstract of the early feasibility study was published in the American Journal of Kidney Diseases and has been posted by the Company on the Presentationssection of its Investor Relations website.
The feasibility study investigated the effectiveness of PEMF during a 2-week trial on reducing Proteinuria (P) in subjects with CKD, evaluating for synergy between Pulsed Electromagnetic Field Therapy (PEMF) and angiotensin receptor blockers (ARBs). Four volunteers with progressive poteinuric nephropathies applied PEMF to their lower-thoracic spine, allowing electromagnetic energy to pulse over both kidneys for 30 min, 3 times a day for 2 weeks. All medications were continued without change, including previously prescribed ARB’s. Urinary spot collections were analyzed for protein to creatinine ratio’s, expressed in grams per day.
During a two-week observational trial, the application of PEMF demonstrated reductions in protein to creatinine ratios expressed on urinary spot collections. Students paired t- test demonstrated in the four subjects, p = 0.06. There were no significant changes in the glomerular filtration rate (MDRD) or mean arterial pressures. No adverse events were reported. The reduction in proteinuria over 2 weeks was arithmetically, but not statistically significant due to small population size. This reduction in proteinuria warrants further study to determine long term effectiveness and possible synergy with RAS blockade.
It’s on fidelity. When I get back to computer (using phone now), I’ll post it.
Mgmt is an absolute joke! What a mistake this was to jump into this pos! Obviously SH are they're only avenue of financing, and they could care less about any of us. People need to stop buying this pos all together and let the dilution drive it down to a penny or even sub-penny, and render their dilution absolutely useless. Maybe then they'll have the incentive they need to find other means of financing.
MSCI Inc downgrades ENDONOVO THERAPEUT from 2 to 1.
BY Investars Analyst Actions - public
— 7:19 AM ET 04/30/2018
On April 29, 2018 MSCI Inc downgraded ENDONOVO THERAPEUT from 2 to
Great job Mgmt! How low can we go??
Nothing happening here today. They’re trying to take it back to 03. Leaving the bid at 0326 so they can drop it.
Has anyone else come across this anywhere? Was looking on Fidelity and came across this today, but it looks like they posted it yesterday:
Accounting & Governance Risk Overview: Endonovo Therapeutics Inc
BY Audit Integrity Research
— 11:53 AM ET 04/02/2018
Endonovo Therapeutics Inc (ENDV) is currently rated as having Aggressive
Accounting & Governance Risk (AGR®), receiving an AGR score that places
them in the 24th percentile
among all companies in North America
rated by GMI, indicating higher accounting and governance risk than
76% of the other companies.
Its strange though, because I can only get to it if I log in, select "Stocks" from the "News & Research" dropdown, then search ENDV, and the link is in the "News" section. If I don't log in, the "News & Events" section doesn't show it anywhere. Or, if I log in and just select ENDV from my Positions, the link doesn't show in the News/Events section at all.
What you know. Sitting at 0368 and all of a sudden the ask drops to 0352. Gee. I wonder if they want to push this down some more.
Every day is Groundhog day here at ENDV.
So they update the website, but funny how they leave the shares listed under stock data at 305,274,764. I'm not sure what the most recent number was, but I'm pretty sure it was over 319M+. It appears that the rest of the "stock data" gets updated, just not the o/s.
The only thing news gets us anymore is increased dilution.
I wish people would just stop buying all together and force their hand.
I think Midas had it right in his post last week. They had financing interest at one point, but greed prevented them from giving up what they considered to be "too much" of the company.
I could be wrong, but I thought that I read somewhere last year that they were planning on presenting results in Q1 of 2018 at an established bio conference (Dont quote me on this. My memory sucks, so this couldve just been a dream)
Uplist? Ill be happy when they throw a little love to their sh and end the games once and for all, so we can finally have a pps that exceeds single digit cents.
Wow. Look at the bid. Theyve got it all the way down at 042. Guess theyre trying to get us back to the 03s today.
I think it was 4/2016. Somebody may want to check me on that though.
Yes. Positive. They closed at $2.68 on 12-7-16.
Click the link below (yahoo charts) and scroll back to 12/2016.
https://finance.yahoo.com/chart/LIVE#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%3D
Here you go. This chart shows the jump (yahoo finance) if you scroll back to 2016.
https://finance.yahoo.com/chart/LIVE#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%3D
Are you looking at December 2017 or 2016?
Here's one more. This one was the pr notice from 11.28.16 that gives the new cusip # and explains why they decided to do it (sounds familliar, but didn't appear to work).
https://globenewswire.com/news-release/2016/11/28/893085/0/en/Live-Ventures-Incorporated-Effects-Reverse-Stock-Split-in-Bid-to-Expand-Investor-Base.html
I think is correct. Here's another link (although this one shows 12/9). It seems right because they closed at 2.68 on 12/7.
https://globenewswire.com/news-release/2016/12/09/896466/0/en/Live-Ventures-Incorporated-Completes-Reverse-Stock-Split.html
I think so. Found it here
https://m.splithistory.com/live/
LIVE did a 1 for 6 rs on 12-8-16. That’s why we see that jump in pps.
Hey bio - So when do you expect to see an end to all of this bs?
Agreed! Not sure how they expect the pps to rise with bs?
MM manipulation + 2Mil avg weekly dilution = 0.047
Not surprised we can’t gain traction.
So when it drops to 05, they tighten up the bid to 0495, but when it goes to 0545/055 they keep t locked at 05...
Looks they’re going to continue with musical pps. Keeping that bid spread at a half-cent so they can keep selling down every time it goes back 055.
Now they’re walking the ask back down as well.
Yup. This is BS. How do other companies break through this crap, yet endv cant?
Also, if they've been shorting this since it was at 02, I dont understand why it took so long for ENDV to take action with shareintel (Although the mms dont seem to care about shareintel)?
Not really sure how much "credibility" shareintel brings to the table. You would think that if they had any credibility whatsoever, the mms would be less "ballsy," instead of doubling down on their games. Since shareintel was mentioned, the mms have basically just been taunting them more and more, and now we sit in the 03s.
They refuse to let us escape the 04s today. Depressing!
Awesome! It would be nice if Zacks and/or another majore analyst firm started covering ENDV again. You would think that the results we've been getting would warrant it.
I think the mms know something big is coming, which is why theyre being more "ballsy" in their manipulations. They obviously could care less about shareintel, as they are Doing everything/anything to drop that pps as low as they can get it. 0549-0579 was theyre "goldylox" zone before this week, but this week they decided to drop it to 04-048 without blinking, and my guess is that they want it lower.
Opened yesterday at .052 with an 05 ask, so it dropped immediately on open and never got back. Then today, open at 049 and after 20 minutes of pin dropping silence, goes to 04? I know the lack of buying isnt helping us, but I think they know something and want this to close as low as possible today.
Back on 1/23, TA showed 316,548,206. Haven't checked since then.
Were sitting at 053 and they've already dropped the ask to 050. Gotta love it.
No worries 1981. Just gets frustrating from time to time and the blood/adrenaline get pumping. I may vent/b!tch, but as long the pps is in the 05s, I'll keep adding to my position weekly. The only thing worse than being stuck in the 05s, is not having enough shares when it finally breaks out of them. lol.
Anyway, good luck to you and everyone else on here as well!
I'm curious as to why you suggest that 1981?
I don’t have the time/patience to read through and find them, but I’m pretty sure many others have expressed thoughts similar to what I just did, many, many times before. Did you suggest the same to all/any of them?
Look, I know that I’ve only been here for a few months and I don’t pretend to be an expert on any of this. That being said, I didn’t know “time served” on this board was a pre-requisite for venting and/or questioning why endv does certain things. While some may have been, not all of the questions I just asked on previous post were rhetorical. I was genuinely asking “is better financing more relevant to our pps than the results they just released”?
I’m really not trying to argue with you or anyone else on here. I’ve got decent money in this stock (at least for me), so when things don’t add up and/or make sense to me, I’m going to chime in, b!tch, question it, vent, etc... no different than anyone else, and it would be nice if it didn’t elicit a “I think you need to consider if this stock is for you,” or “you’ve only been here for a couple of months,” etc... response half of the time. Just because I chime in with a little bit of salt/vinegar after some bs like Thursday, doesnt mean its time to re-evaluate my position and get out. Just means I have time/money invested like everyone else.
Have a nice rest of your weekend!
Hats off to you Craig for trying to stay positive. I’m trying to keep the optimism as well, but having severe difficulty. It’s hard to interpret everything’s that’s been happening in a way that makes me think mgmt actually gives a shwip about their shareholders. Somebody else posted on here a day or two ago that they’re diluting at a rate of 340k shares per day? Really? Mms not holding them back any. The two “stellar” prs that we’ve been waiting for have come and gone, and yet here we sit in 05s. Everyone thought that “we just need a big relevant PR, and this thing will skyrocket.” We got the rio pr, and were stopped dead in our tracks at 0.077, then walked back to the 5s. Then it was “once they release the results, ....” Results came, we couldn’t get beyond 0626, and by the bell we were back in the 5s. Now it seems that many have pointed to better financing as the new savior, and I just don’t know why we should expect a different result? Is better financing better/more relevant than the results they just released?
The one thing that I really dont understand is why release the results PR, if you know the mms won’t let your pps rise? Especially if there is nothing that they (endv or Shareintel) can do about it. Volume was next to nothing the day before and no t-trade went through, so did they need a spike in volume to add more dilution? Couldn’t go back to back trading days with no t-trade? Idk. Either way, feeling like they just take their sh for granted.
Anyway, just extremely disappointing and frustrating. I don’t know what type of event/pr can even be considered a “catalyst” for this company. By definition, a catalyst pushes pps up. All of our so called catalysts just force us to tread water between 05-0549-057.
I figured. Probably 1/26 too and not 1/29.